Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.
You may also be interested in...
Deals Of The Week: Pfizer Management Updates Thoughts On Split
Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.
Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.